Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., October 05, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) announced it has submitted data to the U.S. Food and Drug Administration (FDA) to support use of a booster shot of the Johnson & Johnson COVID-19 vaccine in individuals 18 years of age and older.The submission includes recent results from the Phase 3 ENSEMBLE 2 study that found a booster of the Johnson & Johnson COVID-19 vaccine given 56 days after the primary dose provided 94 percent protection against symptomatic (moderate to severe/critical) COVID-19 in the U.S. (CI, 58%-100%) and 100 percent protection (CI, 33%-100%) again...
Source: Johnson and Johnson - October 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Identical Twins Carry Distinctive Epigenetic Marks: Study
Researchers found more than 800 sites in the genome where the twins bore the same chemical tags.
Source: The Scientist - September 30, 2021 Category: Science Tags: News & Opinion Source Type: news

COVID-19: infection prevention and control (IPC), UK Health Security Agency (updated 29th September 2021)
Guidance on infection prevention and control for COVID-19. Sustained community transmission is occurring across the UK. Update in this version (published 29th September 2021) - removed PDF format for main guidance and combined HTML documents into one. Update in version published 2nd September 2021 - the standard isolation period advised for contacts of cases within inpatient settings is changed back from 10 to 14 days, in line with current healthcare guidance.
Source: Current Awareness Service for Health (CASH) - September 29, 2021 Category: Consumer Health News Source Type: news

Regulatory approval of COVID-19 Vaccine Janssen, MHRA (updated 23rd September 2021)
Information for healthcare professionals and the public about the COVID-19 Vaccine Janssen 23 September 2021Updated the patient information leaflet for COVID-19 Vaccine Janssen 23 June 2021Published the Public Assessment Report for COVID-19 Vaccine Janssen, and a HTML summary of the report.
Source: Current Awareness Service for Health (CASH) - September 23, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
This study compared approximately 390,000 people who received the Company’s single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety, eff...
Source: Johnson and Johnson - September 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with lazertini...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catalytic (i...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 25, 2021 – Johnson & Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine. In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization. In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals pre...
Source: Johnson and Johnson - August 25, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Bitcoin price tags $50K for first time since May
The Bitcoin price reclaimed the major psychological milestone of $50,000 Sunday evening as the crypto markets continue to recover.
Source: Reuters: Health - August 23, 2021 Category: Consumer Health News Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [<80 kg] / 1400 mg [≥80 kg]).[1] These findings will be featured at th...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Vaccination of people working or deployed in care homes: operational guidance, DHSC (updated 16th August 2021)
From 11 November 2021, anyone working or volunteering in a care home will need to be fully vaccinated against coronavirus (COVID-19), unless exempt. 16 August 2021Added translations of the guidance in Albanian, Arabic, Bengali, Chinese (Simplified), Farsi, French, Gujarati, Hindi, Kurdish (Sorani), Nepali, Punjabi (Gurmukhi), Polish, Romanian, Somali, Spanish, Tagalog, Turkish, Ukranian and Urdu. 5 August 2021Added HTML version.
Source: Current Awareness Service for Health (CASH) - August 16, 2021 Category: Consumer Health News Source Type: news

NHS COVID-19 app: privacy information, DHSC (updated 13th August 2021)
Privacy notice and data protection impact assessment for the NHS COVID-19 mobile app. 13 August 2021Updated the English versions of ' NHS COVID-19 app: privacy notice ' and the easy-read (PDF and HTML) to incorporate changes on the self-declaration of vaccination status and age. 11 June 2021Added updated Welsh language version of the privacy notice.
Source: Current Awareness Service for Health (CASH) - August 13, 2021 Category: Consumer Health News Source Type: news

Can Rusty Nails Cause Tetanus?
Discussion Clostridium tetani is a gram-positive bacillus that is anaerobic and spore forming. Tetanus spores are found universally worldwide in the soil and the stool of animals and people. The spores are hardy and can persist in a variety of environments. Contamination through the skin in wounds (especially deep puncture wounds) and the umbilicus are the primary entry points. It is not unusual for the organism not to grow in cultures. The bacteria grow in low oxygen environments and produces a potential neurotoxin which blocks the myoneural junction. Incubation period is 3-21 days, averaging 10 days. Neonatal tetanus gen...
Source: PediatricEducation.org - August 2, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Golden Rice: Triumph for Science
By Paul TengSINGAPORE, Jul 28 2021 (IPS) After almost two decades, Golden Rice was approved last week by the Philippines authorities for use as food. This together with the approval of the bioengineered Bt eggplant represents a landmark victory of science over misinformation; it will provide consumers with improved nutrition (Golden Rice) and safer food (Bt eggplant). Paul TengBIOTECHNOLOGY CROPS have been controversial in spite of overwhelming support for their safety by the scientific community. This is specially so for the class of biotechnology crops commonly called ‘GMO’ or genetically modified organism. The cont...
Source: IPS Inter Press Service - Health - July 28, 2021 Category: International Medicine & Public Health Authors: Paul Teng Tags: Asia-Pacific Biodiversity Climate Change Economy & Trade Environment Food & Agriculture Food Security and Nutrition Headlines Health TerraViva United Nations Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20